Redefining Onyx HD 500 in the Flow Diversion Era.
Publication/Presentation Date
1-1-2012
Abstract
We report the largest US case series results using Onyx HD-500 (EV3), a new liquid embolic agent, in the successful treatment of 21 patients with wide-neck intracranial aneurysms (mean size 4.5 mm), which are at increased risk of incomplete occlusion or recanalization with standard endovascular intervention utilizing detachable platinum coils. All aneurysms were located in the anterior circulation, and three aneurysms presented as acute subarachnoid hemorrhages. Complete aneurysm occlusion was present in 19 of 21 patients (90%). On six-month followup, one patient with an initially small residual neck progressed to total occlusion. Aneurysm recanalization was not detected in any patients on mean follow up of 8.9 months in 11 patients. Four patients experienced transient neurologic deficits in the immediate postoperative period and one in a delayed fashion. Embolization with the liquid embolic agent Onyx appears to be a safe and effective endovascular modality of treatment for wide-neck aneurysms or recurrent aneurysms that had previously failed treatment with detachable coils.
Volume
2012
First Page
435490
Last Page
435490
ISSN
2090-2832
Published In/Presented At
Dalyai, R. T., Randazzo, C., Ghobrial, G., Gonzalez, L. F., Tjoumakaris, S. I., Dumont, A. S., Rosenwasser, R. H., & Jabbour, P. (2012). Redefining Onyx HD 500 in the Flow Diversion Era. International journal of vascular medicine, 2012, 435490. https://doi.org/10.1155/2012/435490
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
22121488
Department(s)
Administration and Leadership
Document Type
Article